Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

Tuesday, 02 April, 2024 | Supplied by: Bio-Rad Laboratories Pty Ltd


Bio-Rad Laboratories has launched a range of validated antibodies for rare cell and circulating tumour cell (CTC) enumeration. Validated for use with the company’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumour heterogeneity and disease progression at various stages.

Bio-Rad’s Genesis Cell Isolation System is a customisable benchtop solution that uses unbiased size-based cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples. After capture, the enriched cells can be recovered for downstream analysis or immuno-stained on-slide for immunofluorescence applications such as enumeration and identification of various CTC types.

The enumeration of captured CTCs provides valuable insights into the surface markers that indicate cancer type and progression, and is critical to understanding the mechanisms of cancer metastasis. For successful enumeration, the antibody reagents require careful selection to ensure not only sensitivity and specificity to the target cell surface marker, but also compatibility with the staining method. Bio-Rad’s range of validated primary and secondary antibodies enables immunostaining of captured CTCs, supporting cancer researchers working in this field.

Online: www.bio-rad.com
Phone: 02 9914 2800
Related Products

Innovative Research Animal Biologicals

Innovative Research offers a comprehensive selection of biological products sourced from various...

EpigenTek EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit

The kit is a complete set of optimised buffers and reagents designed to enrich an RNA fragment...

Cayman Chemical Off-Patent Drug Screening Library (96-Well)

Featuring a curated collection of FDA-approved compounds that are no longer covered under...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd